

ASX ANNOUNCEMENT

MIDKINE CONFERENCE RESULTS

- First global conference on midkine was held 4-6 Nov 2010
- Key opinion leaders from 11 countries attended
- Cellmid's midkine ELISA was launched to the audience
- Novel applications for Cellmid's patents have been discussed

SYDNEY, 10 November 2010: Cellmid Limited (ASX: CDY) held the first ever global meeting of key opinion leaders on midkine between 4th and 6th November 2010 in Sydney. The conference attracted leading researchers and clinicians from eleven countries representing a number of therapeutic and diagnostic fields.

The conference was held on an "invitation only" basis and all discussions have been conducted confidentially to allow the opportunity for new patents as well as scientific and commercial collaborations to arise.

Cellmid's MK ELISA, a highly sensitive and robust blood test for the accurate measurement of midkine, was launched on the first day of the conference to the audience of midkine researchers and clinicians from around the world. In response, Cellmid has received several expressions of interest for the supply of its gold standard test for midkine measurement in blood.

Each of the eleven expert speakers presented published and unpublished data on midkine's relevance in key therapeutic and diagnostic areas. Cellmid will produce a conference booklet, "*Excellence in Midkine Research - Conference Communiqué*", on published information only, which will be provided to participants and will also be made available on Cellmid's website at a later date.

Unpublished data may be subject to future patent applications and will not be included in the *Conference Communiqué*.

Eminent Japanese scientists and discoverers of midkine, Emeritus Professor Takashi Muramatsu and Professor Kenji Kadomatsu, presented keynote speeches on the conference discussing midkine's biological activities, characteristics and therapeutic applications.

"We believe that a number of collaborations will result from the conference including some which will open up new areas for patenting and product development for Cellmid" said CEO of Cellmid Maria Halasz.

"The conference has been an outstanding success with enthusiastic comments from researchers demonstrating the growing interest in midkine" said director of Cellmid, Mr Koichiro Koike.

Conference program results:

- Dr. Kathrin Guenther presented the technical development program in relation to the MK ELISA from BioGenes with validation data on healthy and cancer bearing individuals.
- Dr Sara Svensson introduced patented technology from Lund University on the antibacterial and antifungal activity of midkine in chronic obstructive pulmonary dysfunction (COPD).
- Dr Bernard Maillere from the Institute of Biology and Technologies presented a novel midkine cancer vaccine approach for the treatment of various carcinomas.
- Global leaders in developmental biology, Professors Christoph Winkler and Peter Hitchcock, presented on midkine's role in neurological differentiation and development with implication in stem cell research.
- Leading analgesia expert from the University of San Pablo, Professor Gonzalo Herradon, introduced research on midkine's role in morphine induced analgesia and drug addiction.
- Cancer researcher Dr Mine Erguven introduced her work on how midkine levels correlate to the failure of the treatment of glioblastoma, the most common and most aggressive brain tumour.
- Experts in antisense agents Professor Dai Licheng and Dr Jing Zhong presented advanced treatment options for hepatocellular carcinoma using midkine antisense coated in nano-liposomes.
- Professor Hiroaki Ooboshi from Fukuoka University introduced his work on midkine gene transfer in the treatment of stroke.
- Professor Peter Ferdinandy from Pharmahungary presented unpublished data on midkine's role in the treatment of heart attack.

The next Excellence in Midkine Research Conference is expected to be held in 2012 in Istanbul, at the invitation of Professor Eyhen Bilir, Dr Mine Erguven and Yuzyil University.

End

Contact:

Maria Halasz, CEO

M +61 416 008 413

About Cellmid Limited (ASX: CDY)

Cellmid Limited is a biotechnology company listed on the Australian Stock Exchange. The Company is the owner of the most comprehensive intellectual property portfolio around midkine globally. Midkine is a significant novel therapeutic and diagnostic target. It is a native protein expressed during early cancer formation as well as at the onset of a number of inflammatory processes. Cellmid is committed to the commercialisation of its portfolio of therapeutic and diagnostic products.

Investment in biotechnology companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.